AN INTRODUCTION TO THE
RM-718 STUDY – Part D

Part D of the RM-718 Study is enrolling up to 30 participants to evaluate the safety, tolerability, and effectiveness of an investigational weekly injection of the study drug in adults and adolescents with Prader-Willi Syndrome (PWS).

PWS is a rare genetic condition that leads to physical, mental, and behavioral problems. The defining symptom of PWS is extreme hunger (hyperphagia), which can cause obesity and other complications.

Disclaimer: To be concise, please note that the term "you" refers to "you and/or your child" throughout this document.

WHAT IS A CLINICAL STUDY?

Clinical studies evaluate the safety and effectiveness of potential new medical treatments. Your participation in the RM-718 Study will help us understand whether the study medication may help treat PWS and the hyperphagia and obesity associated with it.

Participation in this clinical study is completely voluntary. Your decision to participate or not participate in this clinical study will not affect the medical care you receive now or in the future. If you are eligible and choose to participate, you will be asked to review and sign an Informed Consent Form that provides more information on how the study works. You may leave the study at any time and for any reason. If you leave the study, you may be asked to attend a follow-up visit to end your participation.

ARE THERE RISKS?

The study medication may cause side effects. You can learn more about potential side effects in the Informed Consent Form. Participants will be monitored for any side effects throughout the clinical study. You must immediately inform the study doctor or staff if you experience side effects or notice any changes to your health during the study.

Learn More About the RM-718 Study

If you would like to learn more, please speak with a study team member or reach out to patientadvocacy@rhythmtx.com. A study team member can tell you if you may be eligible to participate.

https://clinicaltrials.gov/study/NCT06239116

RM 718 STUDY

Cohort D



INTRODUCING THE
RM-718 STUDY
Part D

A study testing an investigational weekly injection study drug in adults and adolescents with obesity due to Prader-Willi Syndrome (PWS)

Rhythm PHARMACEUTICALS

AN OVERVIEW OF THE

RM-718 STUDY Part D

This study includes a weekly injection of the study drug, RM-718. Your participation will last about 8 months throughout a Screening Period, a Study Treatment Period, and a Follow-up Period. If you are eligible, you may also have the option to continue receiving the study drug in a Long-Term Extension (LTE) Period.

All study participants will receive the study drug at no charge (including study related exams, lab tests, procedures, etc.).

FOR THE MAIN PART OF THE STUDY:

You will receive **26 injections** of RM-718 over a **26-week Study Treatment Period**. RM-718 is injected under the skin. If tolerated, the dose will be gradually increased up to the target level.

Your participation in the study will last up to **33 weeks**.

You'll have up to **29 visits**, either at the clinic or at home.

WHAT CAN I EXPECT?

If you qualify and choose to participate in the RM-718 Study, and sign the Informed Consent Form, you can expect the following:

SCREENING PERIOD

- During the Screening Period, the doctor will perform some tests to see if you're eligible. The Screening Period will last up to 4 weeks.

STUDY TREATMENT PERIOD

- You'll have up to 27 visits during the Study Treatment Period, either at the clinic or at home with a visiting nurse, and 26 injections of RM-718. If you are interested in remote visits, ask the study team for more information.
- You'll need to complete some questionnaires on selected visits.
- Blood draws will be performed at different points during the study to help monitor your safety.

SAFETY FOLLOW-UP VISIT

- You'll be asked to return for a Safety Follow-up Visit (SFV) 28 days after your last dose.

LONG-TERM EXTENSION (LTE) PERIOD

- If you're eligible, you may continue receiving the study drug weekly after the Study Treatment Period ends.
- You'll have clinic visits every 12 weeks for health assessments.

AM I ELIGIBLE?

You may be eligible to participate in the RM-718 Study if you:

- Are between 12 and 65 years of age
- Have confirmed diagnosis of PWS as determined by the Investigator at the time of Screening
- A body mass index (BMI) of 30 or more for adults over the age of 18 or a BMI in the 95th percentile for those under 18.

The study team will assess additional eligibility criteria during the Screening process before enrollment.